A Randomized, Double-blind, Placebo and Positive Drug Parallel-controlled Phase IIa Clinical Study Protocol to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple-dose BGM0504 Injection in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 27 Jun 2025
At a glance
- Drugs BGM 0504 (Primary) ; Semaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 23 Jun 2025 Results published in the BrightGene media release.
- 23 Jun 2025 Accordinfg to BrightGene media release the data from this trial has been presented at the 85th Scientific Conference of the American Diabetes Association (ADA).
- 22 May 2025 New trial record